Quality of life(QoL) outcomes including neuropathy associated scale (FACT-T) from a phase II, multicenter, randomized trial of eribulin plus gemcitabine(EG) versus paclitaxel plus gemcitabine(PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)- negative metastatic breast cancer(MBC): Korean Cancer Study Group trial (KCSG BR13-11).

Abstract

10117Background: A phase II, multicenter, randomized clinical trial of EG and PG as first-line chemotherapy for patients with HER2-negative MBC showed that EG was less neurotoxic, but conferred a s...